Literature DB >> 20002887

Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality.

Nathalie Dhomen1, Silvy Da Rocha Dias, Robert Hayward, Lesley Ogilvie, Douglas Hedley, Veronique Delmas, Afshan McCarthy, Deborah Henderson, Caroline J Springer, Catrin Pritchard, Lionel Larue, Richard Marais.   

Abstract

We recently demonstrated that expression of (V600E)Braf in mature mouse melanocytes induces melanoma. Here, we show that expression of (V600E)Braf using the tyrosinase promoter leads to an unexpected embryonic lethality, with the animals dying before, at, or shortly after birth. The mice suffer from a range of developmental defects in the skin, the brain, the eyes and the heart, tissues that are normally colonized by melanocytes. We show that the (V600E)Braf expressing cells are potential melanocytic precursors that are fully transformed, suggesting that (V600E)Braf stimulates proliferation and blocks differentiation of these cells. Our data suggests that the presence of these cells in the organs that are normally occupied by melanocytes leads to severe developmental disruption, resulting in catastrophic defects and leading to death of the individual.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002887     DOI: 10.1111/j.1755-148X.2009.00662.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  11 in total

Review 1.  The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin.

Authors:  David C Whiteman; William J Pavan; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2011-08-16       Impact factor: 4.693

Review 2.  Genetically engineered mouse models of melanoma.

Authors:  Eva Pérez-Guijarro; Chi-Ping Day; Glenn Merlino; M Raza Zaidi
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

3.  Hiding in plain sight: molecular genetics applied to giant congenital melanocytic nevi.

Authors:  Heather C Etchevers
Journal:  J Invest Dermatol       Date:  2014-04       Impact factor: 8.551

4.  Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

Authors:  Aime T Franco; Roberta Malaguarnera; Samuel Refetoff; Xiao-Hui Liao; Emma Lundsmith; Shioko Kimura; Catrin Pritchard; Richard Marais; Terry F Davies; Lee S Weinstein; Min Chen; Neal Rosen; Ronald Ghossein; Jeffrey A Knauf; James A Fagin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

Review 5.  Somatic V600E BRAF Mutation in Linear and Sporadic Syringocystadenoma Papilliferum.

Authors:  Jonathan L Levinsohn; Jeffrey L Sugarman; Kaya Bilguvar; Jennifer M McNiff; Keith A Choate
Journal:  J Invest Dermatol       Date:  2015-05-07       Impact factor: 8.551

6.  A murine model for the development of melanocytic nevi and their progression to melanoma.

Authors:  Tahseen H Nasti; J Barry Cochran; Yuko Tsuruta; Nabiha Yusuf; Kristopher M McKay; Mohammad Athar; Laura Timares; Craig A Elmets
Journal:  Mol Carcinog       Date:  2015-03-18       Impact factor: 4.784

Review 7.  Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.

Authors:  Yoshihiro Hayakawa; Manabu Kawada; Hiroyoshi Nishikawa; Takahiro Ochiya; Hideyuki Saya; Hiroyuki Seimiya; Ryoji Yao; Masahiro Hayashi; Chieko Kai; Akira Matsuda; Tomoki Naoe; Atsushi Ohtsu; Taku Okazaki; Hideo Saji; Masataka Sata; Haruhiko Sugimura; Yuichi Sugiyama; Masakazu Toi; Tatsuro Irimura
Journal:  Cancer Sci       Date:  2016-02       Impact factor: 6.716

8.  Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.

Authors:  Malin Pedersen; Heidi V N Küsters-Vandevelde; Amaya Viros; Patricia J T A Groenen; Berta Sanchez-Laorden; Jacobus H Gilhuis; Ilse A van Engen-van Grunsven; Willy Renier; Jolanda Schieving; Ion Niculescu-Duvaz; Caroline J Springer; Benno Küsters; Pieter Wesseling; Willeke A M Blokx; Richard Marais
Journal:  Cancer Discov       Date:  2013-01-09       Impact factor: 39.397

9.  BRN2 is a non-canonical melanoma tumor-suppressor.

Authors:  Michael Hamm; Pierre Sohier; Valérie Petit; Jérémy H Raymond; Véronique Delmas; Madeleine Le Coz; Franck Gesbert; Colin Kenny; Zackie Aktary; Marie Pouteaux; Florian Rambow; Alain Sarasin; Nisamanee Charoenchon; Alfonso Bellacosa; Luis Sanchez-Del-Campo; Laura Mosteo; Martin Lauss; Dies Meijer; Eirikur Steingrimsson; Göran B Jönsson; Robert A Cornell; Irwin Davidson; Colin R Goding; Lionel Larue
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

Review 10.  Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics.

Authors:  Jiezhong Chen; Renfu Shao; Xu Dong Zhang; Chen Chen
Journal:  Int J Nanomedicine       Date:  2013-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.